Amrutanjan Health Care Limited — Important, 12-02-2025: Financial Result Updates

Amrutanjan Health Care Limited has announced a board meeting where it approved unaudited financial results for the quarter ended 31 December 2024.

Total revenue grew by 4.9% year-over-year to ₹12,275.15 crore, driven largely by innovation in product offerings and enhanced distribution channels, particularly in the OTC segment.

Net profit after tax rose to ₹1,924.57 crore, up 10.3% from ₹1,744.95 crore in the same quarter last year, resulting in an EPS of ₹6.66 compared to ₹6.05 for the previous year. The increase in profitability can be attributed to improved operational efficiency and cost control measures, despite slight fluctuations in material costs.

Operational costs witnessed a rise of approximately 3.2%, primarily due to increased advertising expenditures and logistics costs associated with product expansion. The effective cost management strategies in other areas helped mitigate this rise, reflecting positively on the company's overall cost structure.

The balance sheet remains robust, with healthy liquidity ratios, indicating that the company is well-positioned to handle its operational commitments. Cash flow from operations has improved, attributed to better working capital management.

Strategically, the company seems focused on consolidating its market position while exploring new growth avenues in women's hygiene products. Market sentiment is cautiously optimistic, given the revenue growth and profit margins.

Investor insight suggests a hold position as the company navigates current market dynamics while leveraging expansion opportunities in its product line.